Effect of inhalation of tobramycin for 12 months on reduction of hospitalisation rate in severe COPD;Inhalation von Tobramycin über 12 Monate zur Senkung der Hospitalisationsrate bei schwerer COPD mit gehäuften Hospitalisationen

Pneumologie

Volumn 67, Issue 9, 2013, Pages 514-519

  Haidl, P ^a   Bargon, J ^b   Gessler, T ^c   Pfeifer, M ^d   Randerath, W ^e   Voshaar, T ^f   Wachall, B ^g  

^a KRANKENHAUS KLOSTER GRAFSCHAFT   (Germany)

^b St Elisabeth Hospital   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d Klinik Donaustauf   (Germany)

^e Krankenhaus Bethanien Solingen   (Germany)

^f Krankenhaus Bethanien   (Germany)

^g InfectoPharm   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOBRAMYCIN;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; GOLD STANDARD; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; TREATMENT DURATION;

ADMINISTRATION, INHALATION; AGED; CAUSALITY; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84883558953     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0033-1344344     Document Type: Article

References (23)

1. Global Initiative for Chronic Obstructive Pulmonary Disease Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Executive Summary: 2005; Available at www.goldcopd.com
2. Casaburi R., Mahler D. A., Jones P. W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J: 2002; 19 217 24 (Pubitemid 34162820)
3. Aaron S. D., Vandemheen K. L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med: 2007; 146 545 555 (Pubitemid 351650535)
4. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet: 2003; 361 449 56 (Pubitemid 36173708)
5. Wedzicha J. A., Rabe K. F., Martinez F. J. et al. Efficacy of roflumilast in chronic obstructive pulmonary disease frequent exacerbator phenotype. Chest: 01 11 2012; 10.1378/chest 12-1489
6. Soler-Cataluna J. J., Martinez-Garcia M. A., Roman S. P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax: 2005; 60 925 931 (Pubitemid 41598207)
7. Hill A. T. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med: 2000; 109 288 295
8. Patel I. S., Seemungal T. AR, Wilks M. et al. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax: 2002; 57 759 764 (Pubitemid 34984972)
9. Donaldson G. C., Seemungal T. AR, Bhowmik A. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax: 2002; 57 847 852 (Pubitemid 35178607)
10. Wilkinson T. M., Patel I. S., Wilks M. et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2003; 167 1090 109
11. Murphy T. F., Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis: 1992; 146 1067 1083
12. Geller D. E., Pitlick W. H., Nardella P. A. et al. Pharmakokinetics and bioavailability of aerolized tobramycin in cystic fibrosis. Chest: 2002; 122 219 226 (Pubitemid 34754166)
13. Ramsey B. W., Pepe M. S., Quan J. M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med: 1999; 340 23 30 (Pubitemid 29024680)
14. Ratjen F., Munck A., Kho P. et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE Trial. Thorax: 2010; 65 286 291
15. Ram F. S., Rodriguez-Roisin R., Granados-Navarrete A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev: 2006; 2 CD004403
16. Drobnic M. E., Suñé P., Montoro J. B. et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother: 2005; 39 39 44 (Pubitemid 40052376)
17. Scheinberg P., Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest: 2005; 127 1420 1426 (Pubitemid 46224309)
18. Wilson R., Welte T., Polverino E. et al. Ciprofloxacin DPI non-cystic fibrosis bronchiectasis: a phase II randomized study. Eur Respir J: 20 12 2012; Epub ahead of print
19. Rademacher J., Welte T. Bronchiektasen - Diagnose und Behandlung. Dtsch Arztebl Int: 2011; 108 809 815
20. Murray M. P., Govan J. R., Doherty C. J. et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med: 2011; 183 491 499
21. Albert R. K., Connett J., Bailey W. C. et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med: 2011; 365 689 98
22. Seemungal T. AR, Wilkinson T. MA, Hurst J. R. et al. Long-term erythromycintherapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med: 2008; 11 1139 1147
23. Patel I. S., Vlahos I., Wilkinson T. M. et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2004; 170 400 407 (Pubitemid 39214614)